ITCI - Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | Benzinga
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) ("Intra-Cellular Therapies"), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has completed the sale of an additional 1,027,397 shares of its common stock at a public offering price of $73.00 per share on April 24, 2024, pursuant to the full exercise of the option granted by Intra-Cellular Therapies to the underwriters in connection with its previously announced public offering of 6,849,316 shares of common stock, which closed on April 22, 2024.
All of the shares in the public offering, including the full exercise of the underwriters' option, were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies of approximately $575 million, before deducting underwriting discounts and commissions and offering expenses.
J.P. Morgan, Leerink Partners, BofA Securities, ...